Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8452W HIGH $17.40
Volume
1.22 M
Value Traded
55.24 K
Short % Float
1.06%
Days to Cover
1.7
-71.23%Week
+143.15%1 Month
+47.12%3 Month
-14.17%6 Month
-99.95%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
951.43 K
EPS (TTM)
-22.13
P/E Ratio
-
Ent. Value
-189.57 K
Total Shares
8.25 M
Float Shares
8.25 M
Insiders
6.98%
Institutions
2.62%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
FEED Catalyst Timeline
Dated clinical, regulatory and corporate events for ENvue Medical, Inc.
Past FDA Catalysts and PDUFA Decisions
How FEED actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every FEED program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| UroShield | spinal cord injury | 2023-03-14 | decrease in the number of blockages and infections and an increase in catheter satisfactionRead More | NanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord Injury Evaluators concluded that UroShield has the potential to improve quality of life and reduce healtRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Glibert Christian MichaelNo longer subject to section 1 | Sell | -210,000 | $0.69 | 06/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FEED
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in FEED for Q2 2026. | ||||
Ownership Trends
FEED Short Interest
Shares sold short, counted twice a month.
1.06%
Short % of Float
of tradable shares sold short
41.0K
Shares Sold Short
+2.4% vs prior count
1.7 Low
Days to Cover
trading days of normal volume to buy every short share back
24.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FEED ranks across every disease it competes in
Competitive Position is a premium feature
See how FEED ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFEED News
About ENvue Medical, Inc.
Headquarters969 PRUITT AVE,, TYLER, TX, 77569
BIOPHARMAWATCH ELITE PLUS
Trade the next FEED catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime